INTRODUCTION
Epigenetic modifications of the DNA and of histone proteins, chromatin remodeling and noncoding RNAs (ncRNAs) participate in the regulation of tissue-and developmental stage-specific gene expression without changing the DNA code (1) . Epigenetic patterns are established by enzymes (writers) that catalyze addition or removal of a moiety to DNA or histone proteins such as DNA methyltransferases (DNMTs), histone methyltransferases (HMTs) or histone acetyltransferases (HATs) (Fig. 1) . These patterns are read by enzymes (readers) that detect those modifications and translate this information into an altered chromatin state. We know now that modifications of the DNA or histones can be further modified by enzymes (editors) that interact with these modifications such as TET methylcytosine dioxygenases (Fig. 1) . In general, epigenetic patterns are stable and are transmitted to the daughter cells during mitosis. In diseases, epigenetic patterns break down through yet unknown mechanism and in this way participate in the massive deregulation of hundreds of genes, as seen in cancer (2 -4) . First clues for the underlying mechanisms leading to global epigenetic reprograming in cancer come from the 'Next Generation Sequencing' (NGS) based profiling projects that catalog mutations, structural variations, epigenomic patterns as well as transcriptome data. Here striking observations are the frequent and often recurrent mutations in enzymes involved in establishing epigenetic patterns suggesting a mechanistic link of genetic alterations and aberrant epigenetic reprograming (5) (6) (7) . In this review, we will highlight some of the most recent advances in the field that will help us to understand the molecular mechanisms of gene regulation as well as the pathways that are altered in human disease with a special focus on cancer.
THE GROWING FIELD OF EPIGENETIC ALTERATIONS IN CANCER
A prominent modification of the DNA is mediated by DNMTs and generates 5-methylcytosine (5mC) by the addition of a methyl group to the cytosine base. DNA methylation is commonly found in intergenic regions and repetitive sequences such as satellite repeats and long and short interspersed nuclear elements (LINEs and SINEs), whereas GC-rich promoter sequences are * To whom correspondence should be addressed at: German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Tel: +49 6221 42 3300; Fax: +49 6221 42 3359; Email: c.plass@dkfz.de usually unmethylated. These patterns are drastically disturbed in cancer genomes that are characterized by gain of methylation in GC-rich promoter sequences and loss of methylation in intergenic regions and repeats (1, 8, 9) . Global effects of altered epigenetic patterns in gene regulatory sequences have been uncovered just recently owing to the mapping efforts of the ENCODE project and the availability of large profile data on over 100 cancer cell lines (10) . Loss of methylation by active DNA demethylation processes are mediated by TET methylcytosine dioxygenases, proteins that convert 5mC by oxydation to 5-hydroxymethylcytosine (5hmC) and subsequently to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (11) (12) (13) (14) . The oxidation products may then be removed by the base excision repair pathway member thymidine-DNA glycosylase. In mouse embryonic stem cells (ESCs), 5fC has been found in poised enhancers, sites that are frequently altered in cancer, and in other gene regulatory elements indicating the importance of this epigenetic mark in normal and in disease states. Furthermore, 5fC seems to interact with the enhancer-binding protein EP300 in remodeling epigenetic states of enhancers (15) .
Cancer-specific DNA methylation can serve as a marker for early detection of a disease or as a prognostic marker that helps to classify tumor subgroups with different biological or clinical features. This has been shown for GSTP1 promoter methylation as a marker for early detection of prostate cancer (16) or MGMT methylation as a marker for treatment response in glioblastoma (17) . Utilizing the power of highly quantitative DNA methylation assays, such as Pyrosequencing or MassAR-RAY (18) , it was recently demonstrated that quantitative DNA methylation of a single CpG dinucleotide in the promoter of ZAP70 is able to predict outcome of chronic lymphocytic leukemias (CLL), better than currently existing expression analysis by FACS sorting (19) . Another example is the identification of a DNA methylation marker panel of five genes which identifies a signature-low methylation levels in ALDH1A2 and OSR2 promoters and high methylation levels in GATA4, GRIA4 and IRX4 promoters-that predicts the clinical outcome in HPV-driven oropharyngeal squamous cell carcinoma (20) .
EPIGENETIC KEY PLAYERS AND THEIR CROSSTALK IN EPIGENOME FORMATION
The molecular mechanisms leading to epigenetic deregulation are largely unknown. However, cancer genome sequencing projects frequently detected recurrent mutations in writers, readers or editors of all epigenetic pathways (5 -7). Examples come from sequencing projects in acute myeloid leukemia uncovering mutations in IDH1 or DNMT3A (21, 22 ) that encode enzymes involved in establishing and maintaining DNA methylation. Further examples include ARID1A mutations in non-small-cell lung cancer (23) , CREBBP, EP300 and MLL in small-cell lung cancer (24) and the histone variant H3.3-encoding gene H3F3A in pediatric glioblastoma (25) . A striking example is also the finding of biallelic inactivation of the chromatin remodeling factor SMARCB1 in rhabdoid tumors which is the only recurrent mutation in this tumor (26) . Most of these mutations are associated with altered global DNA or histone modification patterns; however, the underlying cause of these patterns is mostly still elusive with the exception of the H3.3K27M mutation. This mutation occurs in only one of three H3.3-encoding genes (H3F3A) and only in a heterozygous state. H3.3K27M interacts with higher affinity than wild-type H3.3 with the Polycomb Repressor Complex 2 (PRC2). This close interaction leads to an inactivation of the catalytic activity of enhancer of zeste homolog 2 (EZH2), the H3K27me3-generating HMT within this complex. Loss of H3K27me3 is seen genome-wide, associated with massive deregulation of gene expression and alterations in DNA methylation patterns (27 -29) .
LONG NONCODING RNAS
Together with microRNAs (miRNAs), long noncoding RNAs (lncRNAs) comprise a considerable portion of the human genome (30) . MiRNAs and lncRNAs can be targets of or contributors to epigenetic deregulation and, hence, may indirectly or directly contribute to developmental defects and a wide range of diseases including neurological and cardiovascular disorders as well as various types of cancer (for recent reviews [31] [32] [33] [34] . In the following, we put emphasis on some recent findings regarding regulation of or by lncRNAs. By definition, lncRNAs have a length of .200 bp and no protein coding potential; moreover, they are more cell type-specific than protein coding mRNAs. LncRNAs participate in the regulation of protein localization, translation, posttranslational modifications, mRNA stability and chromatin shaping, often by means of their secondary structure (35) .
DLEU1 and DLEU2 are examples of epigenetically deregulated lncRNAs which map to 13q14.3, a frequently deleted region in CLL. Both lncRNAs are aberrantly hypomethylated and upregulated in CLL, independent of cytological aberrations in 13q (36) . Adjacent genes, which do not show aberrant methylation and are known to be involved in modulation of NF-kB 
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signaling, are downregulated, suggesting a suppressive role of DLEU1 and DLEU2 in cis. CTBP1-AS is an androgen-responsive, predominantly nuclear lncRNA antisense to CTBP1 which encodes C-terminal binding protein 1, a corepressor targeting the androgen receptor. Upregulated CTBP1-AS promotes both hormone-dependent and castration resistant tumor growth in prostate cancer (37) . CTBP1 is repressed by recruitment of the RNA-binding transcriptional repressor PSF and histone deacetylases through CTBP1-AS. CTBP1-AS also inhibits tumor-suppressor genes and promotes cell cycle progression in a global, androgen-dependent manner through PSF-mediated mechanisms. CTBP1-AS harbors SINE repeat sequences which are important for the interaction with the RNA-binding domain of PSF (37) .
Circular RNAs (circRNAs) have emerged as novel epigenetic regulators. CircRNAs are more stable than linear RNAs and characterized by unusual splice junctions generated from an acceptor splice site at the 5 ′ end of an exon and a donor site at the 3 ′ end of an exon. An example is circRNA CDR1as, also designated ciRS-7, which is antisense to the CDR1 gene (38) and acts as negative regulator of miRNA miR-7 (39,40). CDR1as complexes with AGO proteins and captures miR-7 in neuronal tissue by virtue of more than 60 conserved miR-7 binding sites. Another possible function of circRNAs may be to serve as a scaffold in the formation of RNA-protein complexes.
DYNAMICS OF THE EPIGENOME IN DEVELOPMENT AND DISEASE
The use of advanced technologies allowing global analysis of minor amounts of tissue samples or cells provided novel fundamental insights into the dynamics of the epigenome in the early mammalian embryo, differentiation and disease. During commitment of somatic cells, changes of the epigenome are moderate, in contrast to a striking reprograming of histone modifications and genomic demethylation in mouse primordial germ cells (PGCs) (for recent reviews 41,42). Global genomic demethylation reprograms the epigenome of PGCs to totipotency and probably occurs by both active and passive mechanisms. Increased levels of 5hmC, the conversion product of 5mC and of the conversion enzymes Tet1 and Tet2 between embryonic day (E) 9.5 and E11.5 of PGCs suggest an active demethylation process which is followed by replication-dependent passive demethylation (43) . Despite global hypomethylation, PGCs display only transient expression of pluripotency genes and have a similar RNA complexity as somatic cells, indicating a tight control of transcript levels in PGCs (44) . Some singlecopy CpGs residing in genes and in the vicinity of intracisternal A particles (IAPs), endogenous retroviral-like sequences, escaped demethylation and may offer an explanation for transgenerational epigenetic inheritance (43, 44) . As a class of genomic elements, IAPs remained highly methylated in PGCs (44) while SINEs, LINEs and other transposable elements retained only low or moderate methylation (45) ; however, only LINE1 showed enhanced transcription in female E16.5 PGCs (44). Upon fertilization, the genome of mouse sperm undergoes drastic demethylation while the methylome of the zygote resembles that of the oocyte, suggesting that the methylome of the zygote is largely defined by the oocyte (46) .
The role of epigenetic mechanisms in adult stem cell differentiation was studied in 19 cell types of the mouse blood and skin cell lineage (47) . In vivo methylation changes at specific genomic loci frequently overlapped with the genes encoding lineage-associated transcription factors (TFs) and their binding sites. Promoter methylation and the histone modifications H3K9me3 or H3K27me3 are known repressive chromatin marks (48) . In line with this, loci and binding sites of myeloid TFs were found to become methylated in lymphoid cells, suggesting that such methylation events may protect against inadvertent activation of differentiation programs in the lymphoid lineage.
An integrative study of 82 human cell lines and tissues demonstrated that hypermethylated regions in cancer cells were enriched for sites known to be bound by NANOG in ESCs, supporting the notion of a stem cell-like signature in cancer (49) . Across cancer types, long-range hypomethylated genomic areas were enriched for cancer-specific binding sites of the PRC2-component EZH2 and its product H3K27me3. The sequence context-dependent relation between DNA methylation and expression in non-cancer cells could be extended by the observation that active genes with their characteristic high methylation of the gene body displayed unmethylated CpG-rich intragenic sequence patches bound by the enhancer-binding transcriptional coactivator EP300.
Aging of hematopoietic stem cells (HSCs) leads to functional impairment and is a possible cause for hematopoietic malignancies in the elderly. Examination of the HSC methylome from differently aged mice revealed an age-dependent hypermethylation of PRC2-regulated genes concomitant with a reduced transcription of genes Ezh2, Suz12 and Eed encoding PRC2 components (50) . The data suggest that PRC2-mediated gene repression may decrease upon aging, thus allowing the DNA methylation machinery to more readily methylate PRC2 target genes. Increased methylation of PRC2 target genes is also a frequent observation in diverse cancers.
TECHNICAL ADVANCES IN EPIGENOMICS
Recent technical and bioinformatic advances for generation and analysis of NGS data were the major driving forces in the flourishing epigenetic research field (51) . Whole-genome bisulfite sequencing (WGBS) is the gold standard to interrogate a tissue-or cell type-specific methylome (Fig. 2) . Bisulfite treatment allows for the discrimination between unmethylated and methylated cytosines: unmethylated cytosines are converted to uracil, while methylated cytosines remain unconverted. The original WGBS approach (52) required microgram amounts of genomic DNA, prohibitive for studies where, for purity reasons, only microdissected tissue or tumor specimen can be used. Such studies are possible now, however, using tagmentation-based WGBS (T-WGBS) (53), a transposase-based approach which requires only nanogram quantities of genomic DNA. Another novel method for low input amounts is post-bisulfite adaptor tagging (PBAT) which applies two rounds of random priming and can even circumvent PCR amplification (54) . Mere bisulfite treatment does not allow for the discrimination between 5mC and the oxidized versions 5hmC, 5fC, 5caC and, hence, screening specifically for these much rarer oxidized cytosine modifications Human Molecular Genetics, 2013, Vol. 22, Review Issue 1 R3 requires different approaches (55) . Therefore, diverse enrichment techniques have been devised to determine the genomic distribution of 5hmC which either make use of a combination of chemical and enzymatic treatment or of chemical treatment and immunoprecipitation (56, 57) . Using glucosylation of 5hmC to protect against TET enzyme mediated further oxidation, 5hmC can now be quantified at single base resolution by sequencing after bisulfite treatment (58) . Similarly, chemical protection of 5fC against bisulfite-mediated deamination allows comparative bisulfite sequencing to quantify 5fC at base resolution (15) . Linking the epigenome with gene regulatory networks which are operative in developmental and disease driving processes requires profiling of activating and silencing chromatin marks as well as the interaction of chromosomal domains in the threedimensional nuclear space. NGS of enriched genomic regions after chromatin fixation followed by immunoprecipitation (ChIP-seq) using antibodies against diverse histone modifications like H3K4me3 or H3K27me3 is now state-of-the-art in many laboratories (Fig. 2) . A single-tube linear DNA amplification approach circumvents sample loss during purification steps by use of a single buffer and, hence, can be applied to samples of only a few thousand cells (59) .
In the interphase nucleus, chromosomes are folded into higher order structures, coined chromosomal territories, in which crosstalk between commonly regulated genes and long-range interactions between genes and their distant regulatory sequences like enhancers take place. Chromosome conformation capture (3C) applies chemical crosslinking of chromatin domains followed by restriction fragmentation and ligation of crosslinked DNA fragments. 3C captures spatially vicinal domains which may be megabases distant from each other (Fig. 2) . Recent technical improvements under the acronyms 5C, Hi-C and ChIA-PET allow deep NGS analysis of many interaction partners or even on a global genomic scale and contribute to an advanced understanding of the genomic architecture and regulatory genetic and epigenetic networks (for recent reviews 60-62).
FUTURE PERSPECTIVES
The epigenetics field is currently experiencing a revolution in the gain of information. This puts a high burden on the bioinformatical analysis and integration of these data sets in order to maximize the information gained from these experiments. Driven by novel genome-wide profiling technologies, the epigenetics community is rapidly learning more how epigenetic mechanisms influence gene regulation. While in the past there was a focus on promoter regions, it is now possible to include enhancer and other regulatory regions, intergenic regions, or even repetitive sequences into an integrative analysis of gene regulation. The field is driven by studies investigating cell proliferation and development in normal cells, however, the knowledge is rapidly applied to diseases such as cancer and cardiovascular disorders. Future work will also shed more light on the molecular mechanisms that lead from a genetic defect to an altered epigenetic pattern and subsequently altered gene expression. This will help to better understand the disease mechanism and to develop improved therapies. Figure 2 Epigenome analysis techniques. The methylome is analyzed by WGBS, the location of histone modifications, DNA binding proteins and promoters by chromatin immunoprecipitation followed by NGS (ChIP-seq), and the higher order organization is analyzed by chromosome conformation capture (3C) including NGS.
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